Girentuximab
(Anti-human Carbonic anhydrase IX mAb, human IgG1-Kappa; WX-G250)
Catalog No.: PC-Ab1117Not For Human Use, Lab Use Only.
Girentuximab (G250) is a monoclonal antibody (mAb) for targeting CA IX, a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC). Carbonic anhydrase IX (CA IX) is the most widely expressed gene in response to hypoxia. Its crucial role in intracellular pH maintenance represents the means by which cancer cells adapt to the toxic conditions of the extracellular milieu..
Girentuximab (G250) is a monoclonal antibody (mAb) for targeting CA IX, a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC). Carbonic anhydrase IX (CA IX) is the most widely expressed gene in response to hypoxia. Its crucial role in intracellular pH maintenance represents the means by which cancer cells adapt to the toxic conditions of the extracellular milieu.
Physicochemical Properties
M.Wt
Formula
Human IgG1-Kappa
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
PBS, pH 7.0
Contains no stabilizers or preservatives
